Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Johnson & Johnson to acquire Mentor for $1.07 billion
Mentor will operate as a stand-alone business unit reporting through Ethicon, a Johnson & Johnson company and provider of suture, mesh and other products for a wide range
Mentor will operate as a stand-alone business unit reporting through Ethicon, a Johnson & Johnson company and provider of suture, mesh and other products for a wide range
Jim Hitchin, SpectraScience’s CEO, said: “This patent is important to the company’s optical biopsy technology because it provides protection in the areas of tissue surveillance, characterization, diagnosis and
Dr Valone was most recently senior vice president of medical affairs at Bayhill Therapeutics where he was responsible for clinical, regulatory, quality and nonclinical toxicology/safety aspects related to
The trial is designed to evaluate the safety and tolerability of SB1518 in patients with chronic idiopathic myelofibrosis (CIMF) and is expected to enroll up to 50 patients.
Pralatrexate is a novel, small molecule chemotherapeutic agent that inhibits dihydrofolate reductase, a folic acid-dependent enzyme involved in the building of nucleic acid, or DNA, and other processes.
ANA598 is Anadys’s investigational hepatitis C non-nucleoside polymerase inhibitor. Anadys is currently enrolling patients in a Phase Ib study evaluating ANA598 for the treatment of patients chronically infected
Under the terms of the transaction, One Equity Partners has acquired the professional wound care product portfolio containing advanced wound care brands such as Promogran matrix wound dressing,
Adhezion said that its proprietary formulation can be used in a variety of applications including as an anti-microbial surgical sealant that creates a protective barrier to prevent infection,
The initial Phase I clinical trial of LX4211 is planned as a double-blind, randomized, placebo-controlled, ascending single- and multiple-dose study in healthy volunteers. This study is designed to
Mr Horner has been a director of Endo since August 2006 and has resigned to pursue other business opportunities. Endo Pharmaceuticals will immediately begin the search for a